The grant is subject to payment of fees and completion of final amendments and formalities. When issued, the patent claims ...

Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better ...

Shares of DURECT Corporation shot up 240% to $1.88 by close of trading Tuesday, after Canada’s Bausch Health agreed to ...

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 16, Mizuho ...

A person using an assumed name accessed the court via Zoom video conferencing software and displayed graphic pornographic ...

Bausch Health to acquire DURECT Corporation, strengthening commitment to developing innovative solutions for patients with liver disease: Laval, Quebec Wednesday, July 30, 2025, 1 ...

随着大数据、物联网以及5G系统应用的日益广泛，数据传输的速度和容量需求急剧增加，硅基电子集成芯片的尺度和计算效率逐渐趋近物理极限。而光子集成芯片以光子为信息载体，具有体积小、速度快、集成度高的优势，在光通讯、量子计算、量子信息处理等领域得到了快速发展 ...

在英特尔、博通、Marvell、英伟达等巨头的联手推动下，CPO（co-packaged optics：共封装光学）这个概念越来越被人熟悉。尤其是在人工智能大模型推高数据中心数据流量传输、“超节点”日渐走红的当下，CPO被提上了紧急议程。

Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.

Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.